EDGAR Filing Documents for 0001683168-18-003041

Form 1-A/A - Offering Statement [Regulation A]: [Amend]

SEC Accession No. 0001683168-18-003041

Filing Date

2018-10-12

Accepted

2018-10-12 17:09:26

Documents

Document Format Files

Seq	Description	Document	Type	Size
1		primary_doc.html	1-A/A
1		primary_doc.xml	1-A/A	15095
2	PRELIMINARY OFFERING CIRCULAR	cns_1aa2-poc.htm	PART II AND III	877901
3	FORM OF ISSUER ACKNOWLEDGMENT REGULATION A OFFERING BETWEEN CNS PHARMACEUTICALS,	cns_1aa2-ex0102.htm	EX1A-1 UNDR AGMT	218581
4	FORM OF OFFERING DEPOSIT ACCOUNT AGENCY AGREEMENT WITH FINTECH CLEARING, LLC	cns_1aa2-ex0801.htm	EX1A-8 ESCW AGMT	121004
5	CONSENT	cns_1aa2-ex1101.htm	EX1A-11 CONSENT	2318
6	TERMS OF USE - FLASHFUNDERS.COM	cns_1aa2-ex1501.htm	EX1A-14 CNSNT SV	142090
	Complete submission text file	0001683168-18-003041.txt		1378083

Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027

Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185 X701

CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)